Skip to content

Minimally Invasive Surgery in Treating Patients With Spinal Tumors

Comparison of Minimally Invasive Approaches of Spine Tumor Surgery

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01308489
Enrollment
7
Registered
2011-03-04
Start date
2012-05-31
Completion date
2014-06-30
Last updated
2015-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult Spinal Cord Neoplasm, Recurrent Adult Spinal Cord Neoplasm, Spinal Bone Metastases, Spinal Cord Metastases

Brief summary

This randomized clinical trial studies minimally invasive surgery in treating patients with spinal tumors. Posterior spinal tumor resection and anterior and posterior spinal tumor resection are less invasive types of surgery for spinal tumors and may have fewer side effects and improve recovery

Detailed description

PRIMARY OBJECTIVES: I. Length of operation (operating room \[OR\] time). II. Estimated blood loss (EBL). III. Complication rate. IV. Neurological preservation. SECONDARY OBJECTIVES: I. Motor strength and sensory level (neurological outcome). II. Bladder and bowel function. III. Post-operative pain. IV. Hospital length of stay (recovery time). V. Arthrodesis. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients undergo posterior spinal tumor resection on day 0. ARM II: Patients undergo anterior and posterior spinal tumor resection on day 0. After completion of study treatment, patients are followed up for 6 months.

Interventions

PROCEDUREtherapeutic conventional surgery

Undergo posterior spinal tumor resection

PROCEDUREquality-of-life assessment

Ancillary studies

Sponsors

National Cancer Institute (NCI)
CollaboratorNIH
City of Hope Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients must have a diagnosis of primary, secondary or metastatic spine tumor and be undergoing any posterior spinal fusion with or without anterior fusion anywhere from occiput to sacrum * Greater than 3 month life expectancy * Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately * All subjects must have the ability to understand and the willingness to sign a written informed consent

Exclusion criteria

* Patients who are not surgical candidates for spine tumor removal, determined by the surgical team * Patients who have undergone previous spine surgery for tumor removal will be excluded * Patients with renal cell carcinoma * As there is an emphasis on blood loss and length of surgery, the critical variable for homogeneity is the vascularity of the tumor; hypervascular spine tumors are regarded by surgeons as amongst the most challenging of cases; by far the three most common hypervascular metastatic tumors are those arising from renal cell carcinoma, thyroid carcinoma and melanoma; these pathologies are usually regarded as a distinct subset for this reason in the majority of studies; because we rarely encounter the later two pathologies in our practice, we chose to include only the former; however, to further homogenize our study population we will exclude all three of the known hypervascular metastatic spine tumors * Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study

Design outcomes

Primary

MeasureTime frameDescription
Estimated blood loss (EBL); in milliliters (ml)Day 0Will be comparing means with the Wilcoxon test.
Length of operation (OR time)Day 0Will be comparing means with the Wilcoxon test.
Complication rateDay 0
Neurological preservationPost operation day 90

Secondary

MeasureTime frameDescription
Length of stayLess than 7 days
Pain symptomsPre-operation, post-op day 3, discharge, post-op days 7, 28, 60, and 90
Assessment of neurologic function using the ASIA (American Spinal Injury Association) Impairment ScalePre-operation, post-op day 3, discharge, post-op days 7, 28, 60, and 90This is an assessment of sensory and motor functions based upon the ASIA Impairment Scale
Evaluation of arthrodesisPost-op day 1, 28, and 90Plain x-ray films and CT scans are used to determine the success of arthrodesis (spinal fusion in this case) which is the artificial induction of joint ossification between two bones via surgery. This is done to relieve intractable pain in a joint which cannot be managed by pain medication.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026